BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On May 1, 2017, Biostage, Inc., or the Company, posted an updated
version of its investor presentation on its website, which the
Company may use from time to time. Investors should read the
updated investor presentation in its entirety, including the
cautionary statement regarding forward looking statements in the
beginning of the presentation. The forward looking statements in
the updated investor presentation involve known and unknown
risks, uncertainties and other factors that may cause the
Companys actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements.
To view the updated investor presentation, please visit the
following link: http://ir.biostage.com/events-and-presentations
The information disclosed under this Item 7.01 is being furnished
and shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, and shall not be
deemed incorporated by reference into any filing made under the
Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such filing.
About BIOSTAGE, INC. (NASDAQ:BSTG)
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world. BIOSTAGE, INC. (NASDAQ:BSTG) Recent Trading Information
BIOSTAGE, INC. (NASDAQ:BSTG) closed its last trading session down -0.017 at 0.328 with 349,267 shares trading hands.
